[1] de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII-renewing consensus in portal hypertension [J]. J Hepatol, 2022, 76(4): 959-974.
[2] Banini B A, Patel S, YU J W, et al. Derivation and validation of a model to predict clinically significant portal hypertension using transient elastography and FIB-4 [J]. J Clin Gastroenterol, 2023, 57(2): 189-197.
[3] Simbrunner B, Villesen I F, Scheiner B, et al. Von Willebrand factor processing in patients with advanced chronic liver disease and its relation to portal hypertension and clinical outcome [J]. Hepatol Int, 2023, 17(6): 1532-1544.
[4] Hametner S, Ferlitsch A, Ferlitsch M, et al. The VITRO Score (Von Willebrand factor antigen/thrombocyte ratio) as a new marker for clinically significant portal hypertension in comparison to other non-Invasive parameters of fibrosis including ELF test [J]. PLoS One, 2016, 11(2): e0149230.
[5] Deng H, Qi X, Guo X. Diagnostic accuracy of APRI, AAR, FIB-4, FI, King, Lok, Forns, and FibroIndex scores in predicting the presence of esophageal varices in liver cirrhosis: a systematic review and meta-analysis [J]. Medicine (Baltimore), 2015, 94(42): e1795.
[6] Sterling R K, Asrani S K, Levine D, et al. AASLD Practice Guideline on noninvasive liver disease assessment of portal hypertension [J]. Hepatology, 2025, 81(3): 1060-1085.
[7] You M W, Kim K W, Pyo J, et al. A meta-analysis for the diagnostic performance of transient elastography for clinically significant portal hypertension [J]. Ultrasound Med Biol, 2017, 43(1): 59-68.
[8] Choi S Y, Jeong W K, Kim Y, et al. Shear-wave elastography: a noninvasive tool for monitoring changing hepatic venous pressure gradients in patients with cirrhosis [J]. Radiology, 2014, 273(3): 917-926.
[9] Zhang X, Zhou L, Liang W, et al. Identification of clinically significant portal hypertension in cACLD individuals with spleen stiffness measurement [J]. Liver Int, 2025, 45(4): e16241.
[10] Osman A M, El Shimy A, Abd El Aziz M M. 2D shear wave elastography (SWE) performance versus vibration-controlled transient elastography (VCTE/fibroscan) in the assessment of liver stiffness in chronic hepatitis [J]. Insights Imaging, 2020, 11(1): 38.
[11] Zhu Y L, Ding H, Fu T T, et al. Portal hypertension in hepatitis B-related cirrhosis: diagnostic accuracy of liver and spleen stiffness by 2-D shear-wave elastography [J]. Hepatol Res, 2019, 49(5): 540-549.
[12] Kennedy P, Stocker D, Carbonell G, et al. MR elastography outperforms shear wave elastography for the diagnosis of clinically significant portal hypertension [J]. Eur Radiol, 2022, 32(12): 8339-8349.
[13] Liu Y, Ning Z, Örmeci N, et al. Deep convolutional neural network-aided detection of portal hypertension in patients with cirrhosis [J]. Clin Gastroenterol Hepatol, 2020, 18(13): 2998-3007.e2995.
[14] Wang C, Huang Y, Liu C, et al. Diagnosis of clinically significant portal hypertension using CT- and MRI-based vascular model [J]. Radiology, 2023, 307(2): e221648.
[15] Dajti E, Ravaioli F, Zykus R, et al. Accuracy of spleen stiffness measurement for the diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a systematic review and individual patient data meta-analysis [J]. Lancet Gastroenterol Hepatol, 2023, 8(9): 816-828.
[16] Jachs M, Hartl L, Simbrunner B, et al. The sequential application of baveno VII criteria and VITRO score improves diagnosis of clinically significant portal hypertension [J]. Clin Gastroenterol Hepatol, 2023, 21(7): 1854-1863.e1810.
[17] Liu C, You H, Zeng Q L, et al. Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306) [J]. Clin Mol Hepatol, 2025, 31(1): 105-118.
[18] Robic M A, Procopet B, Métivier S, et al. Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study [J]. J Hepatol, 2011, 55(5): 1017-1024.
[19] Jachs M, Hartl L, Simbrunner B, et al. Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient [J]. J Hepatol, 2024, 80(5): 744-752.
[20] Petta S, Sebastiani G, Vigano M, et al. Monitoring occurrence of liver-related events and survival by transient elastography in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease [J]. Clin Gastroenterol Hepatol, 2021, 19(4): 806-815 e805.
[21] Semmler G, Yang Z, Fritz L, et al. Dynamics in liver stiffness measurements predict outcomes in advanced chronic liver disease [J]. Gastroenterology, 2023, 165(4): 1041-1052. |
